Publication

Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management?

Journal Paper/Review - Apr 24, 2019

Units
PubMed
Doi
Contact

Citation
Notter J, Bregenzer A, Vernazza P, Kahlert C. Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management?. Swiss Med Wkly 2019; 149:w20053.
Type
Journal Paper/Review (English)
Journal
Swiss Med Wkly 2019; 149
Publication Date
Apr 24, 2019
Issn Electronic
1424-3997
Pages
w20053
Brief description/objective

Nevirapine has an exceptional record for long-term tolerability with few side effects in human immunodeficiency virus (HIV) combined antiretroviral therapy (cART). Owing to relatively frequent hypersensitivity reactions (HSR) (15–25%) in the first 3 months after treatment initiation (especially in patients with a high CD4 count (>250/µl in women, >400/µl in men)), it is being used less and less. However, the rate of adverse events is lower when patients are already under suppressive cART. We present the results of a single centre strategy to offer the switch to a nevirapine-containing regimen and evaluate the potential role nevirapine could play in current antiretroviral treatment.